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1 Drug description 
Generic/Brand name/ATC code:  
Everolimus/ Afinitor/ L01XE10 
Developer/Company:  
Novartis Europharm Limited 
Description:  
Everolimus is a derivative of sirolimus and a selective inhibitor of the 
mammalian target of rapamycin (mTOR), a central regulator of tumour cell 
division and angiogenesis in cancer cells [1]. In cells, everolimus binds to 
the intracellular FK Binding Protein-12 (FKBP-12), forming a complex that 
inhibits activation of the mTOR complex-1. Inhibition of mTOR signalling 
pathway results in the inhibition of T- lymphocyte activation and prolifera-
tion associated with antigen and cytokine stimulation and in the inhibition 
of antibody production [1, 2].  
Everolimus is administered orally. The recommended dose for the treatment 
of pancreatic neuroendocrine tumours (pNET) is 10 mg once daily. 
Management of adverse reactions may require dose alterations. If necessary, 
the dose is reduced to 5 mg daily [2].  
Monitoring of renal function (blood urea nitrogen, urinary protein or serum 
creatinine), of fasting serum glucose and complete blood count is recom-
mend prior to the start of therapy and periodically thereafter [3].  
In patients with severe hepatic impairment everolimus should not be used. 
If patients develop severe symptoms of non-infectious pneumonitis or re-
ceive a diagnosis of invasive systemic fungal infection therapy should be dis-
continued. In case of infections discontinuation should also be considered 
[3].  
2 Indication 
Everolimus is indicated for the treatment of unresectable or metastatic, well- 
or moderately-differentiated neuroendocrine tumours of pancreatic origin in 
adults with progressive disease.  
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3 Current regulatory status  
In Europe, everolimus is approved by the European Medicines Agency 
(EMA) [2] under the trade name Afinitor® for 
 the treatment of unresectable or metastatic, well- or moderately-
differentiated neuroendocrine tumours of pancreatic origin in adults 
with progressive disease (August 2011) [2],  
 the treatment of patients with advanced renal cell carcinoma (RCC) 
whose disease has progressed on or after treatment with VEGF-
targeted treatment (2009), 
and under the trade name Votubia® for  
 the treatment of patients aged 3 years and older with subependymal 
giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS) 
in 2011. In 2010, Votubia® was designated an orphan medicine. 
In 2007 orphan designations were granted for the treatment of RCC and gas-
troenteropancreatic NETs. These orphan designations were withdrawn by 
the marketing-authorisation holder in 2011.  
Everolimus  is also approved in Europe under the trade name Certican  
 for the prophylaxis of organ rejection in adult patients following al-
logeneic renal or cardiac transplant since 2003.  
 
Everolimus is approved by the United States Food and Drug Administration 
(FDA) :  
 under the trade name Afinitor for progressive neuroendocrine tu-
mours of pancreatic origin that is unresectable, locally advanced or 
metastatic in 2011,  
 for the indication SEGA in 2010, 
 and for RCC in 2009 [4], 
 under the trade name Zortress  for prophylaxis of organ rejection in 
adult kidney transplant recipients in 2010 [5].  
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4  Burden of disease 
Neuroendocrine tumours (NETs) comprise a group of neoplasms that origi-
nate from neuroendocrine cells. Even though the nomenclature used is not 
consistent, the most common NETs are carcinoids which arise from lungs, 
bronchi, small intestine, appendix and rectum, whereas pNETs arise from 
the endocrine tissue of the pancreas [6, 7]. pNETs are described as having a 
different response to therapeutic agents and a more aggressive clinical 
course compared to carcinoids [8].  
NETs can be further sub-classified histologically into well-differentiated 
and poorly-differentiated NETs. Furthermore, different grades can be as-
signed to these tumours (i.e. low-grade, intermediate-grade, high-grade) 
which reflect the aggressiveness of the disease [9].  
The term pNET - “islet cell tumour” (islet cells are hormone producing cells 
in the pancreas) is sometimes used as synonym - refers to well-differentiated 
low- or intermediate grade tumours, whereas poorly differentiated high 
grade tumours are referred to as pancreatic neuroendocrine carcinomas [9, 
10].   
If pNETs produce hormones and thus cause specific symptoms of hormone 
hypersecretion, the tumours are “functional” [11] and are called according 
to the main hormone. The most common functional tumours are “insulino-
mas”, “glucagonomas” and “gastrinomas” which present with hypoglycae-
mia (due to insulin), diabetes mellitus (glucagon) or recurrent peptic ulcer 
disease (gastrin). Further types include somatostatinomas, VIPomas and 
PPomas [7, 11]. The malignant potential of functional pNETs depends on 
the type of the tumour and is low in insulinomas but high in glucagonomas 
or gastrinomas [7, 9, 11].  
Non-functional pNETs, in contrast, do not produce specific clinical syn-
dromes, and they thus present at later stages, e.g. with symptoms of tumour 
bulk [11]. Up to 90% of the non-functional tumours are malignant [6].  
Even though functionality is discussed as having an impact on prognosis, 
functional tumours are classified according to grade and staging, like non-
functional tumours. The evidence is conflicting which of these tumours are 
more frequent [2, 6, 10, 11]. Estimates for non-functional tumours range be-
tween 15% [6, 11] and 75% [2, 10], but functional status may also change 
with treatment or over time [12]. 
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PNETs are rare, with an incidence of 0.2-0.4 per 100,000 people per year [7]. 
Peak incidence is around 40 - 69 years [6]. Malignant pNETs may account 
for circa 1% of pancreatic cancers by incidence and 10% by prevalence 
(NCCN). In Austria [13] approx. 1,400  new cases of pancreatic cancer were 
seen in the year 2009. Based on these figures, 14 new malignant pNET cases 
per year could be expected to occur (own calculation). 
The majority of pNETs are sporadic and risk factors are not well under-
stood. They may occur as part of an inherited genetic syndrome, such as 
multiple endocrine neoplasia (MEN) type 1 or MEN2. In that case patients 
require different strategies than those with usually solitary, sporadic tu-
mours [6, 11]. 
The clinical course of the disease is said to be highly variable, even in the 
presence of liver metastases [14]. Five-year survival with localised and re-
sected pNET is around 55%, but only about 15% when the tumour is not re-
sectable [11].  
5 Current treatment 
Therapy of choice for patients with localised pNETs is surgical excision. 
Since patients with pNET frequently develop liver metastases, surgery of 
liver metastases and the primary tumour is also indicated, if possible.  
For patients with unresectable liver metastases palliative treatment options 
comprise hepatic regional therapies, including arterial embolisation, ra-
dioembolisation, chemoembolisation and local ablative therapy such as ra-
diofrequency ablation and cryoablation. 
However, the majority of patients with advanced disease have unresectable 
tumours. If the disease is stable, tumour burden low and the tumour asymp-
tomatic careful observation may be best [6]. For patients who are clinically 
symptomatic from tumour bulk and/or those with significantly progressing 
disease systemic treatment options include [6, 15]: 
 Biologically targeted agents such as sunitinib which is approved for 
the treatment of unresectable or metastatic well-differentiated pNET 
with disease progression in adults. 
 Somatostatin analogues include octreotide and lanreotide. Patients 
with symptoms of hormone secretion can be considered for treatment 
to manage their symptoms. Only octreotide is approved for sympto-
matic treatment of VIPomas and Glucagenomas with clinical features. 
 Cytotoxic chemotherapy for unresectable or metastatic disease. Com-
binations (none of which are approved in pNET) include 
 streptozocin combinations: streptozocin plus doxorubicin, strepto-
zocin plus 5-fluorouracil and doxorubicin 
 dacarbazine- and temozolomide-based regimens: dacarbazine alone 
or temozolomide  either alone or in combination with other agents 
(e.g. capecitabine) 
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6 Evidence 
In addition to a free text search, a systematic literature search was con-
ducted in Embase, Ovid Medline, CRD Database and Cochrane Library. 91 
references were identified. Regarding the approved indication pNET, one 
phase III trial (Radiant-3 [16]) and 2 phase II trials [8, 12] were identified.   
6.1 Efficacy and safety - Phase III studies 
Table 1: Summary of efficacy  
Study title A randomised double-blind phase III study of RAD001 10mg/d plus best supportive care versus placebo 
plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine tumour [2, 16] 
Study identifier ClinicialTrials.gov number: NCT00510068, RADIANT-3, EUdraCT: 2006-006819-75, Sponsor's 
Protocol Code Number: CRAD001C2324 
Phase III, randomised, double-blind, multicentre (82 centres in 18 countries), placebo controlledDesign 
Duration  Enrolment: July 2007 until May 2009 
Median follow-up: 17 months 
Cut-off date for final analysis: 28th February 2010 
Funding Novartis Oncology 
Hypothesis Superiority 
Intervention Everolimus 10mg (could be reduced to 5mg) once daily plus best suppor-
tive care (BSC) 
Treatment 
groups 
Control Placebo once daily plus BSC 
Progression-free 
survival (primary 
outcome) 
PFS Time from randomization to documented disease progression de-
fined according to RECIST 1.0 (19) or death due to any cause 
Overall survival OS Time from randomisation to death due to any cause 
Endpoints and 
definitions 
Objective response 
rate 
ORR Complete response or partial response according to RECIST 1.0 
Results and analysis 
Analysis descrip-
tion 
Primary analysis: The primary analysis was performed in the full analysis set population and 
based on the local investigator assessments. The primary analysis was analysed using a strati-
fied one-sided log-rank test. The test was stratified by whether or not patients had received 
prior cytotoxic chemotherapy and by WHO performance status (0 versus 1 or 2) at baseline. 
PFS and OS were analysed by Kaplan–Meier method and study groups compared with log-rank 
test. Groups were stratified according to prior receipt of chemotherapy and WHO performance 
status. Hazard ratio was estimated with stratified Cox proportional hazards model. 
Analysis popula-
tion 
Inclusion Advanced (unresectable or metastatic) biopsy-proven pNET, radio-
logical documentation of disease progression within 12 months, con-
firmed low-grade or intermediate-grade NET, measurable disease per 
RECIST 1.0, WHO – PS ≤2 
one phase III trial in 
pNET 
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Exclusion Poorly-differentiated or high-grade NET; hepatic-artery embolisation 
within 1-6 months or cryoablation or radiofrequency ablation of he-
patic metastasis within 2 months before enrolment; severe or uncon-
trolled medical condition; prior therapy with an mTOR inhibitor 
Characteristics Median age: I 58 years (range 23 -87) vs. C 57 years (20 – 82)  
Gender: Females: I 47% vs. C 42%, Male: I 53% vs. C 58% 
WHO-PS: 0-1: I 97% vs. C 97%  
Histology: well differentiated: I 82% vs. C 84%, moderately: I 17% vs. 
C 15%, unknown: I 1% vs. C 1%  
Prior therapy: biopsy: I 74% vs. C 72%, other surgery: I 59% vs. C 
59%, any medications: I 58% vs. C 58%, chemotherapy: I 50% vs. C 
50%, targeted therapy: I 5% vs. C 7%, immunotherapy: I 3% vs. C 
4%, hormonal therapy: I 1% vs. C 1%, other: I 10% vs. C 13%, any ra-
diotherapy: I 23% vs. C 20%  
Further characteristics: liver metastases: I 92% vs. C 92%; gastri-
noma, glucagonoma, VIPoma, insulinoma or somatostatinoma: pre-
sent in 24% (I and C) 
Treatment group Control Intervention 
Number of subjects 203 207 
PFS by INV (months) 
Median 
95% CI 
 
4.6 
3.1-5.4 
 
11.0 
8.4-13.9 
PFS by IAC (months) 
Median 
95% CI 
 
5.4 
4.3-5.6 
 
11.4 
10.8-14.8 
OS (months) 
Median 
95% CI 
 
NA 
 
 
NA 
 
Descriptive sta-
tistics and esti-
mated variability 
 
 
 
 
ORR (%) by INV 
95% CI  
Partial Response (%) 
Complete Response (%)  
Stable Disease (%) 
Progressive Disease (%) 
Unknown (%) 
2.0 
0.5-5.0 
2.0 
0 
50.7 
41.9 
5.4 
4.8 
2.3-8.7 
4.8 
0 
72.9 
14.0 
8.2 
Comparison groups  Intervention vs Control 
Hazard ratio 0.35 
95% CI 0.27-0.45 
PFS (INV) 
P value (log-rank test) <0.001 
Hazard ratio 0.34 
95% CI 0.26-0.44 
PFS (IAC) 
P value (log-rank test) <0.001 
Hazard ratio  1.05 
95% CI  0.71-1.55 
OS (data cut-off Febru-
ary 2010) 
P value (log-rank test) 0.594 
Hazard ratio 0.99 
95% CI 0.68 - 1.43 
Effect estimate 
per comparison 
OS (90-Day Safety Up-
date, data cut-off June 
2011) 
P Value NA 
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Hazard ratio 0.89 
95% CI 0.64 - 1.23 
OS (CHMP requested 
update, data cut-off 23 
February 2011) 
P Value NA 
ORR P value 0.091 
Abbreviations: WHO-PS= WHO - Performance status, INV= local investigator assessment, IAC= central adjudica-
tion committee assessment, NA = not available, CHMP = Committee for Medicinal Products for Human 
Use 
 
Table 2: TRAEs according to grade, TRAEs leading to discontinuation or dose modification, AEs leading to 
death (study NCT00510068 [16]) 
Grade (according to CTC version 
3.0) 
Outcome, n (%) Control (n=203) Intervention 
 (n=204) 
Stomatitis 34 (17) 131 (64) 
Rash 21 (10) 99 (49) 
Diarrhoea 20 (10) 69 (34) 
Fatigue 29 (14) 64 (31) 
Infections 12 (6) 46 (23) 
Nausea 37 (18) 41 (20) 
Peripheral oedema 7 (3) 41 (20) 
All Grades, occurring at least in 
≥20% 
Decreased appetite 14 (7) 40 (20) 
Stomatits 0 (0) 14 (7) 
Anaemia 0 (0) 12 (6) 
Hyperglycaemia 4 (2) 11 (5) 
Grade 3 or 4, occurring at least in 
≥4% 
Thrombocytopenia 0 (0) 8 (4) 
Stomatitis (<1) (10) 
Pneumonitis NA (0) NA (7) 
Thrombocytopenia NA (0) NA (7) 
Diarrhoea NA (0) NA (4) 
Most common TRAEs leading to 
dose modification 
Anaemia NA (0) NA (3) 
TRAEs leading to discon-
tinuation 
NA (2) NA (13) Others 
AEs leading to death 1 (<1) 7 (3) 
Abbreviations: TRAE= treatment related adverse event, AE=adverse event, NA = not available 
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In the phase III Radiant-3 trial [2, 16] everolimus 10mg daily (N=207) was 
compared to placebo (N=203) in patients who had advanced, low- or inter-
mediate-grade pNET and radiologic progression within the previous 12 
months. Patients were stratified according to prior chemotherapy and 
WHO-PS [16]. Primary end point was progression-free survival (PFS), 
originally planned as per central adjudication committee assessment, but 
then amended to PFS as per local investigator assessment. Secondary end 
points included overall survival (OS), overall response rate (ORR) and 
safety. Treatment continued until disease progression, unacceptable toxicity, 
drug interruption for ≥ 3 weeks, or withdrawal of consent. Data for PFS was 
censored at time of last adequate tumour assessment before the cut-off date. 
Tumour measurements (CT, MRT) were performed at baseline and repeated 
every 12 weeks. Scans were reviewed at the local site and centrally.  
The primary efficacy analysis was conducted when 274 PFS events had oc-
curred ; median follow-up time was 17.0 months. Median PFS (by local in-
vestigator assessment (INV)) was with 11.0 months significantly longer in 
the everolimus arm than with 4.6 months in the placebo arm (HR: 0.35, 95% 
CI: 0.27-0.45, p<0.001). This was supported by the results of the central ad-
judication committee (IAC) assessment which found 11.4 months compared 
to 5.4 months (HR: 0.34, 95% CI: 0.26–0.44, p<0.001). In contrast, ORR was 
low in both groups (everolimus: 4.8% vs. placebo: 2.0%) and even these 
numbers were achieved only due to partial responses, corresponding to 36 
patients needed to be treated with everolimus to achieve one partial response 
which would have not been achieved with placebo. The authors correctly 
mentioned that the primary benefit from everolimus is thus stabilisation of 
disease rather than tumour shrinkage. No statistically significant difference 
was observed between the treatments with respect to OS as of cut-off date 
February 2010. But these data were not mature and since 148 (73%) of the 
203 patients initially assigned to placebo crossed-over to open-label ever-
olimus, any future investigation of the presence of a survival benefit will be 
confounded.  
A subgroup analysis showed consistent results across all subgroups in PFS 
(by e.g. age, gender, WHO-PS, liver involvement, well- vs. moderately differ-
entiated tumour grade, prior vs. no prior chemotherapy). Exploratory inves-
tigation of biomarker levels (CgA, NSE, Ki67) did not show that they were 
predictive of response.  
In the Radiant-3 trial treatment related adverse event (TRAEs) leading to 
discontinuation were seen in 13% of the patients who received everolimus 
vs. 2% of those with placebo. Dose adjustment was required by 59% of pa-
tients in the everolimus group vs. 28% of those in the placebo group. Most 
commonly this was due to stomatitis, pneumonitis and thrombocytopenia. 
Serious TRAEs occurred in 22% of individuals treated with everolimus 
group and in. 4% treated with placebo. 3.4% (i.e. 7 patients) in the ever-
olimus and 0.5% (i.e. 1 patient) in the placebo group died due to AEs, yield-
ing a number needed to harm of 34 patients. Causes of death in patients 
treated with everolimus included acute renal failure, acute respiratory dis-
tress (ARDS), cardiac arrest, death with unknown cause, hepatic failure, 
pneumonia and sepsis. In one case ARDS was the AE considered to be re-
lated to everolimus. The most frequently occurring TRAEs of all grades were 
stomatitis, rash and diarrhoea, those of grade 3 or 4 were stomatitis, anaemia 
and hyperglycaemia.  
phase III trial in pNET 
to show superiority of 
everolimus versus 
placebo in PFS 
PFS was 11.0 compared 
to 4.6 months, HR was 
0.35 (significant) 
no significant difference 
in OS but immature data 
and cross-over to 
everolimus allowed 
 
 
 
 
subgroup analysis 
supported PFS results 
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thrombocytopenia 
 
most common grade 3 
or 4 events were 
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6.2 Efficacy and safety - further studies 
A phase II, open-label, non-randomised, uncontrolled trial [2, 12] 
(NCT00363051) investigated everolimus 10mg daily in patients with metas-
tatic pancreatic NETs who experienced progression on or after chemother-
apy. Patients were stratified according to prior octreotide treatment. Stra-
tum 1 (s1) consisted of 115 patients who had not received prior octreotide, 
whereas stratum 2 (s2) comprised 45 patients with prior octreotide treat-
ment, who continued with their entry dose of octreotide long-acting release 
(LAR intramuscularly every 28 days) in addition to everolimus.  
Primary endpoint was ORR (ICR). It was seen in 9.6% of patients in stratum 
1 (95% CI: 4.9-16.5%) and in 4.4% (95% CI: 0.5-15.1%) in stratum 2. Again, 
these results are attributable to partial responses only. Median PFS (IRC) 
was 9.7 months (95% CI: 8.3-13.3 months) in s1 and 16.7 months (95% CI: 
11.1 months–not available) in s2. Median OS was 24.9 months (95% CI: 
20.2–27.1 months) in s1, but had not been reached for s2. The most frequent 
TRAEs of any grade were stomatitis, rash, diarrhoea, fatigue and nausea. 
The most frequent TRAEs of grade 3 or 4 were asthenia in s1 (5%) and 
thrombocytopenia in s2 (9%). AEs most commonly requiring dose adjust-
ment or interruption were hyperglycaemia (8%), stomatitis (7%) and diar-
rhoea (5%) in s1 and thrombocytopenia (11%), pyrexia (11%) and stomatitis 
(9%) in s2. Pneumonitis or interstitial lung disease was seen in 6/7 patients 
(s1/s2), all were grade 1 or 2.   
Another phase II non-randomised, uncontrolled trial [8] investigated ever-
olimus 5mg/d and 10mg/d in combination with octreotide LAR (30mg every 
28 days) in patients with advanced (metastatic or unresectable) low- to in-
termediate-grade NETs. 30 patients with carcinoid and 30 with islet cell tu-
mours (including MEN1) were enrolled; proportionally more patients with 
carcinoid were treated with 5mg/d whereas those with islet cell tumours re-
ceived mainly 10mg/d everolimus.  
ORR was 20% in the intention to treat and 22% in the per protocol popula-
tion. Again, these results were solely attributable to partial responses (carci-
noid: 17%, islet cell tumour: 27%).  Overall, median PFS was 60 weeks (95% 
CI 54-66 weeks) - 63 weeks in patients with carcinoid (95% CI: 55-71 weeks) 
and 50 weeks in those with islet cell tumours (95% CI: 31-70 weeks). Median 
PFS was 50 weeks with 5mg/d (95% CI: 23-78 weeks) and 72 weeks with 
10mg/d (95% CI: 60-83 weeks). Most common grade 3 or 4 AEs were fatigue, 
diarrhoea and hypophosphataemia (all: 11%). In the 5mg/d cohort no pneu-
monitis was seen, but in the 10mg/d cohort 9% had grade 2 and 3% had 
grade 3 pneumonitis. 
7 Estimated costs 
The price for one package Afinitor® 10 mg, containing 30 tablets and there-
fore lasting for a month, is € 3,600 [17]. This corresponds to € 120 for one 
tablet daily. These costs occur as long as clinical benefits can be observed 
and toxicity remains acceptable. In the phase III trial, Radiant-3, median 
duration of treatment with everolimus was 38 weeks. Assuming the same 
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treatment duration, overall costs in addition to expenses for previous thera-
pies would be € 31,920.  
Because the preferred sequence of available therapies in advanced pNET is 
not clear, some of these costs could be additive and others alternative to ex-
isting ones. 
8 On-going research  
One on-going phase III trial investigating everolimus in NETs was found on 
the EU Clinical trials Register [18]:  
 CRAD001k24133: An open-label, multi-centre, expanded access study 
of everolimus in patients with advanced NET. The study evaluates the 
safety of everolimus in patients with advanced NET of gastrointesti-
nal, lung or pancreatic origin.  
A range of on-going or recently completed phase II trials investigating ever-
olimus in NETs including those of the pancreas, was found on ClinicalTri-
als.gov [19]. These trials investigate everolimus as mono-therapy or in com-
bination with pasireotide, temozolomide, octreotide, or octreotide and 
bevacizumab (NCT00843531, NCT01469572, NCT01229943, NCT01374451, 
NCT00576680). 
A range of on-going phase III trials investigating everolimus in the following 
indications were found on ClinicalTrials.gov [19]:  
 breast cancer, skin cancer, B-cell lymphoma, gastric cancer, oe-
sophagogastric junction cancer, hepatocellular carcinoma 
 renal, cardiac, liver and lung transplantation 
 polycystic kidney disease, renal interstitial fibrosis, coronary artery 
disease 
range of on-going phase 
II trials in pNET 
range of on-going phase 
III trials in different 
indications 
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9 Commentary  
Everolimus (Afinitor®) was approved by the EMA for the treatment of ad-
vanced pNET in patients with progressive disease in August 2011 [2]. This 
decision was mainly based on the results of the Radiant-3 trial, which 
showed a prolongation of PFS by 6.4 months (as assessed by the local inves-
tigators) for patients treated with everolimus in comparison to patients 
treated with placebo. No advantage in OS was observed with everolimus 
compared to placebo as of the final analysis, but data were not mature and 
since patients were allowed to cross-over to the active treatment arm, the 
analysis will be impaired. Therefore, it remains unclear whether the ob-
served improvement in PFS will translate into survival benefit. 
In patients with unresectable or metastatic pNET, but stable and asympto-
matic disease, careful observation may be best [6]. For patients with pro-
gressive disease treatment options are limited. Among available therapies, 
sunitinib, another targeted therapy, was approved by the EMA for the 
treatment of unresectable or metastatic, well-differentiated pNET with dis-
ease progression in November 2010 [20]. For sunitinib, a gain of 5.9 months 
in PFS was found in comparison to placebo within a phase III trial [21].   
Since tumour response was observed in only 4.8% of patients treated with 
everolimus, all of which were partial responses, the effect of everolimus pri-
marily lies in disease stabilisation. Hence it is questionable if patients with 
considerable symptomatic tumour bulks will benefit best from everolimus or 
if chemotherapeutic regimens which have yielded higher response rates are 
preferable [6, 15]. Therefore, head-to-head studies comparing these regi-
mens would be of interest in order to elicit the most beneficial therapy. In 
the absence of comparative efficacy data the choice of agents thus may also 
be based on the toxicity profiles [15]. 
For poorly differentiated, highly aggressive malignancies other treatment 
options are recommended (such as platinum-based chemotherapy [15, 22]). 
Also, everolimus has not shown to be superior to placebo in carcinoid tu-
mours, because one phase III study, the Radiant-2 trial, failed to show that 
everolimus plus octreotide had a significant effect on PFS (boundary for sta-
tistical significance was not met), OS or ORR in these tumours [2, 23].  
Another open question concerns the best sequence of therapies. EMA’s 
Committee for Medicinal Products for Human Use (CHMP) mentioned that 
due to the low number of treatment-naïve patients in the trial assessing 
sunitinib, evidence for the first-line setting is limited [20]. The Radiant-3 
trial does also not clearly answer in which setting everolimus is indicated 
best, because about half of the study population had received prior chemo-
therapy and the other half had not. However, at least a subgroup analysis of 
the Radiant-3 trial provides some results on the influence of prior or no 
prior chemotherapy on PFS, always favouring the everolimus group.  
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As quality of life was not included as an endpoint in Radiant-3, it is not 
known whether the improvement in PFS was achieved without negatively af-
fecting quality-of-life. Also, dose adjustments were necessary in 59% of pa-
tients in the everolimus group (C 28%). The most common TRAEs making 
dose adjustment necessary were stomatitis, pneumonitis, thrombocytopenia, 
diarrhoea and anaemia and 3.4% in the everolimus and 0.5% in the placebo 
group died due to AEs [16]. According to the CHMP safety of everolimus in 
pNET has shown to be largely consistent with what is already known from 
previous studies in oncology. Adverse events were mostly low-grade and re-
versible, but were higher compared to other indications such as renal cell 
carcinoma. In the safety population (pooled data set of phase III studies Ra-
diant-3, Radiant-2 and phase II trial NCT00363051) the incidence of grade 3 
and 4 AEs was around 70% [2]. 
As pNETs are very rare tumours which affect only few people, overall costs 
for everolimus therapy are in the first instance not high for this indication. 
Because the drug is currently tested as combination therapy in phase II 
studies with drugs like pasireotide, temozolomide, octreotide, or octreotide 
and bevacizumab, costs for the treatment of pNET patients might increase 
considerably. Since everolimus is also under investigation for several other 
indications such as breast cancer, skin cancer, B-cell lymphoma or gastric 
cancer, the potential for off-label use is high.  
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